Senator Josh Hawley has taken a significant step in the ongoing debate over abortion pills with his introduction of the Safeguarding Women from Chemical Abortion Act. This legislation is a refined version of a previous bill that sought to ban the popular abortion drug mifepristone. With this new proposal, Hawley aims not only to prohibit mifepristone’s use but also to empower women to take legal action against the manufacturers he claims profit from an inherently dangerous product.
In a statement to Fox News Digital, Hawley asserted, “The science is clear: The chemical abortion drug is inherently dangerous to women and prone to abuse,” highlighting his concerns about both the safety of the drug and the financial motives of companies like Danco Laboratories. He believes urgent action is necessary to protect women’s health and safety. If enacted, his bill would strip FDA approval for mifepristone, classifying its distribution for abortion as a violation of federal law.
Mifepristone has been a central component of the abortion dialogue in recent years, particularly since it accounted for 63% of all abortions in the United States in 2023, according to data from the Guttmacher Institute. In taking a hardline stance against the drug, Hawley aligns himself with a growing number of voices calling for stricter regulations on abortion, reflecting a broader push from pro-life advocates.
The proposal also addresses past concerns raised by Hawley regarding the risks associated with mifepristone. Last year, he introduced a separate bill encouraging the FDA to implement safeguards, allowing women who experienced complications to sue telehealth providers and pharmacies. Notably, research conducted by the Ethics and Public Policy Center (EPPC) underscores these risks, revealing that side effects from mifepristone use occur at rates 22 times higher than what the FDA’s approved label suggests. The EPPC’s data indicates that over 10% of women report severe health issues, such as infection or hemorrhaging, after using the medication.
The legislative climate surrounding mifepristone has shifted, especially following the Biden administration’s revised rules permitting the drug to be prescribed through telehealth. Critics like Hawley argue that this development poses additional risks to women, as it potentially reduces oversight and medical consultation. His sense of urgency is evident in his communication with FDA Commissioner Marty Makary, where he implored the FDA to re-evaluate the available data and implement necessary safeguards. “The health and safety of American women depend on it,” he stated, emphasizing the weight of the issue.
Legal challenges concerning mifepristone have also shaped the discourse. In 2024, the Supreme Court issued a unanimous ruling against a challenge from the Alliance for Hippocratic Medicine aimed at reversing FDA approval of the drug. The Court’s decision upheld access to mifepristone through telehealth and mail, noting that the plaintiffs lacked standing. However, the ruling did not delve into the drug’s safety or efficacy, leaving critical questions about its use unanswered.
As the debate advances, Hawley’s legislative efforts underscore a relentless push from some factions in Congress to reevaluate the guidelines surrounding abortion medications. With this new bill, he aims to assert that women’s health and safety should be paramount. This chapter in the mifepristone story is emblematic of a larger national conversation about the intersection of healthcare, women’s rights, and regulatory practices.
"*" indicates required fields
